Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dorsey:
I could view the posts up till about 1/2 hr. ago, as I said the last ones were dated 1/20 - (mostly all oobe, what else),
just tried again and "Page cannot be displayed" message re-appeared.
It almost looks as though they are having tech difficulties, but, I may be wrong!
Take care,
Ann
Well, I am able to get in, but, latest posts are dated 1/20 - haven't tried posting there yet to test.
Ann
Looks like RB is back in business!
Ann
DNAP 3-D Bionfronmetics Capabilities:
http://www.ibia.org/biometrics/industrynews_view.asp?id=69
Ann
Family Roots looks at Family Tree:
http://www.csmonitor.com/2005/0428/p14s02-stct.html
An
Gratli:
To my recollection, Tony did state that we would not be privy to much information on the cases DNAP is working on, because it could adversely affect court cases.
Ann
It's almost 11:30 a.m. in CA - just got online and RB & NAPS boards are down. Wonder what's up?
Ann
Power-packed for DNAP:
http://transobj.workopolis.com/servlet/Content/fasttrack/20050625/DNA25?section=Biotech
Ann
DNAP - DNA Crime-scene profiling:
http://www.paternity-test-kits.com/dna-crime-scene-profiling.htm
Ann
I don't recall seing this news release:
http://press.arrivenet.com/business/article.php/691653.html
Ann
DNAPrint genomics' Business Partner Biofrontera AG Completes 20 Million Euro Bond Placement
SARASOTA, Fla., Sept. 6, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTC BB:DNAG.OB - News), which holds an 18% stake in German pharmaceutical company Biofrontera AG, today announced that Biofrontera has completed a 20 million euro bond placement.
``We believe our investment in Biofrontera will prove to be beneficial to DNAPrint genomics and to our shareholders,'' said DNAPrint genomics President and Chief Executive Officer Richard Gabriel. ``It validates our decision to build a collaborative relationship with Biofrontera in advance of its anticipated initial public offering.''
``Biofrontera is an excellent business partner for us because of its drug-product pipeline,'' said Hector J. Gomez, Ph.D., Chairman and Chief Medical Officer at DNAPrint genomics. ``We are pleased with our relationship with Biofrontera, and we have the highest confidence in its management team. We are confident the new funding will assist Biofrontera in advancing its drugs into the market.''
Mr. Gabriel and Dr. Gomez both are members of Biofrontera's Board of Directors.
``DNAPrint genomics, Inc. and its support were crucial to our securing this new financing,'' said Prof. Hermann Lubbert, Chief Executive Officer of Biofrontera AG. ``We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs,'' he concluded.
Biofrontera already is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.
Ann
Dorsey:
OT: "I know I was cheating with Garlique"
I won't tell your wife - lol
Ann
Dorsey:
OT:
Your regimen sound "thumbs up!" Bragg is the best brand of apple cider vinegar. I also use raw garlic in anything I can. Chop it up in salsa, eat a clove with a sandwich, slices of Avocade w/Wishbone Dressing and olive oil w/ chopped up garlic. The reason I mention raw as opposed to a capsule - is when you slice garlic it releases the beneficial component called alicin, which is the most medicinal part of garlic - so therefore, when it's cooked in any form, it looses it's greatest benefits. Of course, I well realize, also, that one might not like the flavor of garlic and doesn't want the lingering odor. Citrus peel will take of that. It's strange, since I've eaten it so long, I no longer have to worry about any offensive breath. Can't figure out why.....but AM I'M GLAD!
Newbies, looking for DD here, please don't be too harsh on me for veering off the subject! - lol
Ann
Figured it out - Froggy is "Frogdreaming" - the alias is "Frogdreamin" - but, wasn't it was nice while it lasted? - lol
Ann
Another one from Frog:
("Forgive me, Father, for I have sinned?")
By: frogdreamin
15 Jan 2006, 08:31 PM EST
Msg. 351997 of 352007
(This msg. is a reply to 351980 by bag8ger.)
Jump to msg. #
bag8ger,
"Yes, I am an idiot, and always have been. My new cause is dnag! and I will suppor them from now on!
regards,
Frogdreamin"
Ann
From the RB board:
By: frogdreamin
15 Jan 2006, 02:46 PM EST
Msg. 351959 of 352007
Jump to msg. #
To All:
"I just wanted to say that over all the years that I have been here I have been a real 1st class pompous jerk.
I have insulted many people that did not deserve it, and YES I admit that Dnaprint Genomics is a great company!!
It is going to be very lucrative soon...So If you have the extra cash to invest now is the time!
regards,
Frogdreamin"
Ann
Grateful et al - The PBS Special coming up in Feb.:
http://www.pbs.org/aboutpbs/news/20050713_africanamericanlives.html
Ann
Thanks, Arch
Ann
Gratl:
He is working behind the scenes on this show and his job is to coral stars for an interview. He had to screen all new movie releases for this event, but, was is 8 behind, due to a hectic schedule. Show rehearsals today. Thanks for asking - Guess that's showbiz! - lol
Ann
OT:
One of my sons is covering the Grammy Awards on E-Entertainment, Monday...hope you all don't mind if I brag!
OT
Ann
From 1/3/05 filing:
"It is anticipated that genomics spending at pharmaceutical companies will increase to a level of $13 billion by 2010 from nearly $2.5 billion in 2000 (as reported by a IMS Health Services report and several other industry reports such
as Ernest & Young's pharmaceutical industry report). Current spending is largely concentrated in the discovery phase. By the end of the decade, however, spending in discovery and clinical development will be roughly equivalent. Analysts have
suggested that over 50% of clinical trials will use genomic testing in the near future. According to Data Monitor (Reuters Business Insight Report), the global market for genomics based diagnostic products will reach $3.3 billion by 2005.
The current market is valued at $1.5 billion (2002). Genome Technology Magazine predicted in July of 2002 that the DNA-based diagnostics market will grow by 50% and reach $3.7 billion in four years (2006). "The molecular diagnostics market
will expand to $12 billion by 2010. About half of this ($6 billion) will be attributed to knowledge gained from genomics" according to K.K. Jain, M.D., author of `Molecular Diagnostics,' a current market research report.
Ann
2
Pres. Bush allocates One bilion dollors...DNAP mentioned
http://www.synergeneprofiling.fr/news2.asp
Ann
Tony Frakis statement that our technology is so impactful and thought provoking...read about it...
http://www.human-performancesurvival.com/content/view/1365/2
Ann
Along w/Beth Israel
Ann
We are on Semaphore's Client List:
http://www.sema4usa.com/clients.htm
Ann
Another DNA Phenomics press release - followed by "About DNAPRINT"
http://www.dnaphenomics.com/pressrelease6-15-05.php
Ann
Jerry Wicks, President of Senecio Software:
"According to Dr. Jerry Wicks, the project's Principle Investigator (PI) and President of Senecio Software, "since race is obviously a social construct, we do not consider this DNA test to be a measure of race, nor are we proposing it replace the widely accepted self-report, parental, and observational measures commonly used in surveys or collected on administrative records.
As further explained by Dr. Wicks, "there is also a huge unmet need within the health care sciences, medicine and pharmacology for precise and objective measures of bio-geographical ancestry. Just about everyday we learn of a new medical study reporting significant differentials in pharmacological effects on people with different ancestral backgrounds. This research project should make it easier for DNAPrint's genomic-based test to be incorporated into more NIH funded biomedical research studies."
Ann
Hey, Team!
Later,
Ann
Gratli:
"Thank you for all you do"
It's all a part of investor involvement and I'm glad to be a part of it - thanks, Gratli.
Take care,
Ann
Coffee:
"it'll all come together soon"
Have to think it will happen!
Take care,
Ann
Caught:
We'll see..........................Ann
DNAP's link w/DNA Phenomics - the dots are starting to connect:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Arch:
"I am sorry if I upset you ladies
with my hard core fight game plan."
Nah, I've been in here too long to let these distract me. Just be yourself, and more power to you.
Ann
Arch:
"I wish her well."
And I wish us all well, in return. Let the games begin!
Ann
Here's......Barbara!
http://www.npr.org/templates/story/story.php?storyId=4777986
Ann
Re-read from Nov.:
"DNA Print Pharmaceuticals to Combine Computer Modeling With Genetics to Improve Drug Development
SARASOTA, FL -- (MARKET WIRE) -- 11/08/2005 -- DNAPrintT genomics, Inc. (OTC BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division, which was recently acquired from Kenna Technologies, Inc., is preparing to launch its services contract business for the pharmaceutical and biotechnology industries.
By incorporating DNAPrint's pharmacogenomics contract services with those of the Computational Biology Division, the end result will be a unique solution for optimizing clinical trials. DNAPrint will demonstrate to drug developers that they can learn more about a new drug's patient benefit as well as an optimum dosing regimen.
The computational biology scientists at DNAPrint Pharmaceuticals have developed a system for analyzing complex biological processes. "Our offering is pragmatic," says Dr. Barbara Handelin, General Manager of Computational Biology. "Even with an imperfect understanding of disease and human physiology, we have shown that we can create highly predictive models that improve the understanding of researchers. We are especially excited to demonstrate to potential clients how modeling can work synergistically with genetic studies of drug response."
Ann
Dr. Handelin's discertation from NAME Meeting - 10/05:
"Barbara Handelin, Ph.D., Director of Diagnostics at DNAPrint genomics, Inc. discussed the DNAWitness technology in a presentation on the final day of NAME's annual meeting on Wednesday at the Millennium Biltmore Hotel. The annual meeting, whose theme was "Emerging Issues in Forensics Pathology," was attended by medical examiners and coroners from across the United States and Canada.
Dr. Handelin, a molecular geneticist and an early developer of DNA based tests in medicine and forensics, explained how DNAWitness technology can be utilized in identifying the victims of crimes or disasters.
"John or Jane Doe cases where there are no identifying personal effects or anyone who can provide positive identification of a victim are not uncommon challenges in the coroner or ME's office and typify mass casualty situations such as the tsunami in Southeast Asia," Dr. Handelin said following her presentation. "In many cases, the remains may be too degraded for making personal identification. One of the primary and routine characterizations that medical examiners make in body identification is physical appearance, including racial or ethnic characteristics such as 'Caucasian male or Asian female, approximately 30 years of age.' This can often be a subjective, inferred assessment. In contrast, DNAWitness technology can provide a direct and objective description of a deceased person's genetic ancestry. and South Asian or other genetic groupings. Such delineation could be helpful in locating family members or demonstrating relatedness to community or family."
Ann
Geob:
OT:
"My New years Resolution"
An interesting and unusual resolution - but, glad you're around...(glub) - lol
Ann
BTW - where is Geob?
Ann
Frog:
OT:
"Eventus stultorum magister"
meaning "Riggot?" - lol